Latest Breaking News On - Professor morten sommer - Page 1 : comparemela.com

UTILITY therapeutics Ltd Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review

UTILITY therapeutics Ltd Announces Financing Led by the AMR Action Fund and FDA Acceptance of PIVYA New Drug Application with Priority Review
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomMorten sommerHenry skinnerTom hadleyAction fundDrug administrationPrescription drug user fee actQualified infectious disease productNew drug applicationPriority reviewProfessor morten sommer

UTILITY therapeutics Ltd Announces Financing Led by the AMR Action

UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action .

City ofUnited kingdomTom hadleyHenry skinnerMorten sommerAction fundNews networkDrug administrationPrescription drug user fee actQualified infectious disease productNew drug applicationPriority reviewProfessor morten sommerHadleychief executive officertel

UNION therapeutics COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication

UNION therapeutics COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication The Lancet Regional Health - Europe has published the results of UNION therapeutics phase 1 study of inhaled and intranasal niclosamide products (UNI91103 and UNI91104) The study endpoints were to assess the safety profile and the pharmacokinetic profile of niclosamide when administered as a nasal spray and as an inhalation product (nebulizer) The study was placebo-controlled and conducted in healthy volunteers No adverse effects were identified, paving the way for further investigation in COVID-19 patients On the basis of these results UNI91103 has been selected as the first intervention of the PROTECT-V study, which recently received UK Urgent Public Heath prioritization

United kingdomJulia wilsonInstitut pasteurMorten boesenDrona smithMorten sommerCambridge universityInnovation fund denmarkUnited kingdom kidney researchLancet regional health europeUniversity of cambridgeActivity researchJw communicationsUrgent public health prioritizationLancet regional healthVibeke backer

UNI91103,developed by UNION therapeutics A/S,selected as first agent for prophylactic COVID-19 PROTECT-V study in high-risk patients

UNI91103,developed by UNION therapeutics A/S,selected as first agent for prophylactic COVID-19 “PROTECT-V” study in high-risk patients UNI91103 is a nasal spray delivering niclosamide - a potent inhibitor of SARS-CoV-2 with in-vitro potency >40x higher than remdesivir - to the nasal cavityUNI9110.

United kingdomMelanie leeKim kjMorten boesenDrona smithMorten sommerSeed fundAddenbrooke charitableCambridge biomedical research centreRegulatory agencyUniversity of cambridgeMarie louise jersin communicationsPhilanthropic fundAddenbrooke charitable trustCambridge university hospitalsKidney research united kingdom